The Immune-Image consortium covers all relevant elements of the value chain of immunotracer development. Our consortium has the expertise and capabilities to design, synthesize, evaluate and validate new immunotracers in a strongly translational and reverse-translational manner: from bench to bedside and back.
Immune-Image consists of 21 key stakeholders from across 9 countries, bringing together their extensive expertise, infrastructure and stakeholders.
![](https://www.immune-image.eu/wp-content/uploads/2020/01/institutions.png)
10
academic and medical institutions
![](https://www.immune-image.eu/wp-content/uploads/2020/01/pharmaceutical.png)
7
pharmaceutical companies (EFPIA)
![](https://www.immune-image.eu/wp-content/uploads/2020/01/companies.png)
4
SMEs
![](https://www.immune-image.eu/wp-content/uploads/2020/01/map.png)
GOVERNANCE
The governance structure of Immune-Image on a strategic level involves a General Assembly, Management Board, Workpackages leaders.
![](https://www.immune-image.eu/wp-content/uploads/2020/01/GOVERNANCE.png)